Autolus Therapeutics plc
AUTL evidence brief
What we can confirm
- BioSniper Score:
- 6.5 / 10
- Market Cap:
- $521.7M
- Lead Asset:
- aucatzyl (Approved)
What it means
What to watch
Prepared research question
What matters most for AUTL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AUTL
Autolus Therapeutics plc (AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing, and delivering next-generation programmed T cell therapies, with one approved product (AUCATZYL/obe-cel) for relapsed/refractory B-cell precursor acute lymphoblastic leukemia and a pipeline extending into autoimmune indications.
Key risk: Net loss persists
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$521.7M
Cash Runway
—
Lead Asset
aucatzyl (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 8 clinical trials for Autolus Therapeutics plc.
Autolus Therapeutics plc (AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing, and delivering next-generation programmed T cell therapies, with one approved product (AUCATZYL/obe-cel) for relapsed/refractory B-cell precursor acute lymphoblastic leukemia and a pipeline extending into autoimmune indications.
- AUCATZYL (obecabtagene autoleucel) is approved for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia [pipeline].
- Net product revenue from AUCATZYL was $45.7 million in Q2 2026, a 119% year-over-year increase [news · published 2026-08-11].
- Cash & equivalents stood at $171.4 million as of 2026-06-30 [sec].
- FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to obe-cel for systemic lupus erythematosus and lupus nephritis in September 2026 [news · published 2026-09-09].
- A Phase 1 CARLYSLE trial in systemic lupus erythematosus is ongoing, with updated data submitted for presentation at ACR Convergence 2026 [news · published 2026-10-05].
What works
- AUCATZYL revenue grew 119% year-over-year in Q2 2026, reaching $45.7 million, and full-year 2026 guidance was raised to $140–$150 million [news · published 2026-08-11].
- The company secured a five-year, interest-only credit facility of up to $250 million with Perceptive Advisors, with $75 million funded at close, strengthening its capital base [news · published 2026-08-11].
- Obe-cel received FDA RMAT designation for systemic lupus erythematosus and lupus nephritis, potentially accelerating development [news · published 2026-09-09].
What to weigh
- Despite revenue growth, the company reported a net loss of $39.1 million for the six months ended 2026-06-30 [sec].
- AUCATZYL faces competition from blinatumomab (Blincyto), inotuzumab ozogamicin, and brexucabtagene autoleucel (Tecartus) in its approved indication [pipeline].
- The company is not yet profitable, as noted in a September 2026 news report stating 'Autolus (AUTL) Still Isn’t In The Black' [news · published 2026-09-12].
From the filings
Quoted directly from source documents.
AUCATZYL is approved for r/r B-ALL
“Indication: adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia ("r/r B-ALL") Phase: Approved”
Q2 2026 net product revenue and growth
“Net product revenue hit $45.7 million, up 119% from $20.9 million a year earlier”
News · September 12, 2026
Risks & what to watch (3)›
Key risks
- Net loss persists — Net loss of $39.1M for H1 2026; company not yet profitable [sec] [news · published 2026-09-12]
- Competition in approved indication — AUCATZYL competes with blinatumomab, inotuzumab ozogamicin, and brexucabtagene autoleucel [pipeline]
- Dependence on single product — All reported revenue comes from AUCATZYL; pipeline candidates are in Phase 1/2 [news · published 2026-08-11] [pipeline]
What to watch
- Full-year 2026 AUCATZYL revenue achievement against raised guidance of $140–$150 million [news · published 2026-08-11].
- Data readout from Phase 1 CARLYSLE trial in SLE at ACR Convergence 2026 (November 6-11, 2026) [news · published 2026-10-05].
- Enrollment and interim data from the pivotal Phase 2 LUMINA study of obe-cel in refractory lupus nephritis [news · published 2026-09-09].
- Progress of obe-cel Phase 2 trial in progressive multiple sclerosis [pipeline].
Sources: Catalysts · News · Pipeline · Generated October 12, 2026 · How we verify sources →
Run Autolus Therapeutics plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Autolus Therapeutics plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 5.59 · 0% dilution
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
84
Total value held
$184.2M
| Holder | Shares | Value |
|---|---|---|
| mak capital one llc | 33,621,487 | $46.4M |
| blackstone inc. | 20,485,611 | $28.3M |
| syncona portfolio ltd | 16,640,720 | $23.0M |
| armistice capital, llc | 15,800,000 | $21.8M |
| tetragon partners gp ltd | 9,500,000 | $13.1M |
| schroder investment management group | 9,489,345 | $12.1M |
| frazier life sciences management, l.p. | 4,447,910 | $6.1M |
| bnp paribas asset management holding s.a. | 3,361,156 | $4.6M |
| laurion capital management lp | 3,316,626 | $4.6M |
| renaissance technologies llc | 2,299,499 | $3.2M |
Showing top 10 of 84 institutional holders of Autolus Therapeutics plc. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 7.6%
- Days to cover
- 9.1
- Shares short
- 13,088,539
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AUTL short interestFrequently asked questions
What is the AI investment thesis for Autolus Therapeutics plc?
Autolus Therapeutics plc (AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing, and delivering next-generation programmed T cell therapies, with one approved product (AUCATZYL/obe-cel) for relapsed/refractory B-cell precursor acute lymphoblastic leukemia and a pipeline extending into autoimmune indications.
What is Autolus Therapeutics plc's lead drug candidate?
Autolus Therapeutics plc's most advanced tracked candidate is aucatzyl (Approved) for adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia ("r/r B-ALL").
Who is the CEO of Autolus Therapeutics plc?
Dr. Christian Martin Itin Ph.D. is the chief executive officer of Autolus Therapeutics plc (AUTL).
Where is Autolus Therapeutics plc headquartered?
Autolus Therapeutics plc (AUTL) is headquartered in London, United Kingdom.
What therapeutic areas does Autolus Therapeutics plc focus on?
Autolus Therapeutics plc develops therapies across Oncology, Gene Therapy, Neurology, Immunology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.